Prognostic implications of impaired longitudinal left ventricular systolic function assessed by tissue Doppler imaging prior to transcatheter aortic valve implantation for severe aortic stenosis
verfasst von:
Guglielmo Gallone, Francesco Bruno, Teresa Trenkwalder, Fabrizio D’Ascenzo, Fabian Islas, Pier Pasquale Leone, Philipp Nicol, Costanza Pellegrini, Enrico Incaminato, Pilar Jimenez-Quevedo, Hector Alfonso Alvarez-Covarrubias, Renato Bragato, Alessandro Andreis, Stefano Salizzoni, Mauro Rinaldi, Adnan Kastrati, Federico Conrotto, Michael Joner, Giulio Stefanini, Luis Nombela-Franco, Erion Xhepa, Javier Escaned, Gaetano M. De Ferrari
Change in longitudinal left ventricular (LV) systolic function serves as an early marker of the deleterious effect of aortic stenosis (AS) and other cardiac comorbidities on cardiac function. We explored the prognostic value of tissue Doppler imaging (TDI)-derived longitudinal LV systolic function, defined by the peak systolic average of lateral and septal mitral annular velocities (average S’) among symptomatic patients with severe AS undergoing transcatheter aortic valve implantation (TAVI). 297 consecutive patients with severe AS undergoing TAVI at three european centers with available average S’ at preprocedural echocardiography were retrospectively included. The primary endpoint was the Kaplan Meier estimate of all-cause mortality. After a median 18 months (IQR 12–18) follow-up, 36 (12.1%) patients had died. Average S’ was associated with all-cause mortality (per 1 cm/sec decrease: HR 1.29, 95%CI 1.03–1.60, p = 0.025), the cut-off of 6.5 cm/sec being the most accurate. Patients with average S’ < 6.5 cm/sec (55.2%) presented characteristics of more advanced LV remodeling and functional impairment along with higher burden of cardiac comorbidities, and experienced higher all-cause mortality (17.6% vs. 7.5%, p = 0.007), also when adjusted for in-study outcome predictors (adj-HR: 2.69, 95%CI 1.22–5.93, p = 0.014). Results were consistent among patients with preserved ejection fraction, normal-flow AS, high-gradient AS and in those without LV hypertrophy. Longitudinal LV systolic function assessed by average S’ is independently associated with long-term all-cause mortality among TAVI patients. An average S’ below 6.5 cm/sec best defines clinically meaningful reduced longitudinal systolic function and may aid clinical risk stratification in these patients.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AS
Aortic stenosis
CI
Confidence interval
EF
Ejection Fraction
HF
Heart failure
HR
Hazard ratio
IQR
Interquartile Range
LV
Left ventricle
STS PROM
Society for Thoracic Surgery Predictive Risk of Mortality
TAVI
Transcatheter aortic valve implantation
TDI
Tissue Doppler Imaging
VARC
Valve Academic Research Consortium
Introduction
Left ventricular (LV) responses to aortic valve stenosis (AS) are associated with impaired prognosis. The chronic increase in afterload imposed by AS leads to LV remodeling to counteract the elevated wall stress [1]. When LV hypertrophy is unable to fully compensate for the pressure overload, reduced longitudinal shortening ensues with impairment of myocardial contractility, well before overt global systolic dysfunction becomes apparent [2]. The described response is highly heterogenous, influenced by factors including sex, arterial systemic hypertension, coronary artery disease and amyloidosis, which are highly prevalent in AS and may interact with the clinical benefit of aortic valve replacement [3‐6].
By integrating information on LV responses to AS and concomitant cardiac comorbidities, longitudinal systolic function may provide important prognostic value in patients with AS in whom transcatheter aortic valve implantation (TAVI) is being considered as a treatment [7]. While this concept has been proven for speckle tracking-derived systolic global longitudinal strain [8, 9], no study explored the prognostic role of tissue Doppler imaging (TDI)-derived longitudinal systolic function among symptomatic patients with severe AS prior to TAVI.
Anzeige
TDI-derived peak systolic velocity at the mitral annulus (S’) is a widely available index with numerous advantages for the outlined purpose: it is easily obtainable and highly reproducible, sensitive to early longitudinal contractile dysfunction [10], and with demonstrated prognostic predictive value in cardiac conditions including coronary artery disease, mitral regurgitation and heart failure with preserved ejection fraction (EF) [10‐12]. Furthermore, the use of S’ may help in circumventing several limitations of speckle tracking-derived strain parameters, including difficulty of application, inter-vendor reference values heterogeneity and inter-observer variability [13], making it a powerful bed-side tool for the clinician.
The present study aims to characterize the clinical and echocardiographic correlates of TDI-derived peak systolic velocity at the mitral annulus and to assess its prognostic value among unselected symptomatic patients with severe AS undergoing TAVI.
Methods
Study design
Unselected consecutive patients with severe AS undergoing TAVI from January 2017 to December 2018 at three international Tertiary Centers (Deutsches Herzzentrum München, Munich, Germany; Hospital Clinico San Carlos, Madrid, Spain; Città della Salute e della Scienza Hospital, Turin, Italy) with available TDI-derived longitudinal systolic function measurements at preprocedural echocardiography were retrospectively included in this study.
TAVI was performed according to local expertise and standard techniques. All patients provided written informed consent before the procedure. The registry was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki.
Anzeige
Echocardiographic assessment and data collection
Baseline clinical, echocardiographic and laboratory variables along with clinical follow-up data were prospectively collected at each institution and retrospectively analyzed. Baseline echocardiography was performed in all patients within 3 months before the TAVI procedure. When available, echocardiographic follow-up data were also collected. The echocardiographic evaluation was independently performed by experienced cardiologists who were blinded to patient outcomes.
Echocardiographic exams were performed according to the guidelines of the American Society of Echocardiography [14]. LV volumes and LV mass were determined utilizing standard techniques. LV EF was calculated measuring volumes with a biplane measurement from the apical views using the modified Simpson’s method. Trans-mitral early (E) and late (A) velocities and E wave deceleration time were measured by spectral pulsed-wave Doppler ultrasound at the mitral leaflet tips. TDI was performed adjusting gain and frame rate to get an appropriate tissue characterization. Peak systolic (S′) and early (E′) velocities of the lateral and medial mitral annulus were measured by pulsed-wave TDI from the apical four-chamber view and the average was calculated (Fig. 1). Diastolic dysfunction was evaluated and graded according to the guidelines of the American Society of Echocardiography [14]. The aortic valve area was calculated by the continuity equation, and the maximum pressure gradient across the restrictive orifice was estimated by the modified Bernoulli equation. Mean transaortic pressure gradient was calculated averaging the instantaneous gradients over the ejection period on the continuous-wave Doppler recordings. LV stroke volume was calculated multiplying the systolic velocity–time integral at the LV outflow tract per its area and was indexed to body surface area (SVi). The severity of valvular regurgitation was determined on a qualitative scale (mild, moderate, and severe), according to the current guidelines for the management of patients with valvular heart disease [15].
Fig. 1
Measurement of peak systolic (S’) velocities by 2-dimensional tissue Doppler imaging. S’ represents the peak myocardial longitudinal systolic shortening velocity during ejection assessed by TDI. S′ velocities are measured at the level of the lateral (left panel) and medial (right panel) mitral annulus by pulsed-wave TDI from the apical four-chamber view. Average S’ is calculated as the mean of the lateral and medial S’ velocities. TDI is performed adjusting gain and frame rate to get an appropriate tissue characterization
×
The Society for Thoracic Surgery Predictive Risk of Mortality (STS PROM) score [16] and the EuroSCORE II [17] were prospectively calculated.
Study endpoints
The primary endpoint was all-cause mortality at follow-up. Secondary endpoints were a composite of all-cause mortality or hospitalization for heart failure (HF) at last follow-up and Valve Academic Research Consortium (VARC)-2 defined adverse outcomes assessed at 30 days [18].
Statistical analysis
Categorical variables are expressed as number and percentages, continuous variables are expressed as mean ± standard deviation or median and interquartile range (IQR) as appropriate. Unpaired t test or nonparametric Mann–Whitney U test were used for comparisons of continuous variables and chi-square test was used for categorical variables. Peak systolic average of lateral and septal mitral annular velocities (average S’) was analyzed both continuously and at the best cut-off value to predict the primary endpoint determined by Receiver Operating Characteristic (ROC) curve analysis applying the Youden’s J statistic.
Kaplan–Meier and Cox proportional hazard models were performed to evaluate cumulative event rates of the primary endpoint at long-term follow-up and results are presented as hazard ratio (HR) and 95% confidence intervals (CIs). To produce meaningful outcome estimates, maximum follow-up length was truncated at 18 months (corresponding to the 50th percentile of available follow-up length in the study population).
A multivariate Cox proportional hazards analysis was performed to assess the independent association of average S’ with all-cause mortality, and all-cause mortality or HF hospitalization. All the variables with a univariate p < 0.10 were entered into the models.
Subgroups analyses were carried according to relevant variables (EF: < 50% vs ≥ 50%; stroke volume index [SVi]: < 35 ml/m2 vs ≥ 35 ml/m2, mean transvalvular gradient: < 40 mmHg vs ≥ 40 mmHg, LV hypertrophy: LV mass index ≥ 115 gr/m2 for male, ≥ 95 gr/m2 for female vs < 115 gr/m2 for male, < 95 gr/m2 for female).
Anzeige
An exploratory analysis was carried in a subgroup of patients with available post-TAVI discharge echocardiography to assess the prognostic implications of changes in average S’.
A p < 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS (version 24.0, SPSS Inc., Chicago, Illinois, US).
Results
Study population and outcomes
Overall, 297 unselected patients with severe AS undergoing TAVI and with available TDI-derived longitudinal systolic function measurements constituted the study population. Baseline clinical and echocardiographic characteristics are described in Tables 1 and 2.
Table 1
Distribution of baseline clinical characteristics in the overall study population and stratified by average S’ status
Overall population (n = 297)
Average S' < 6.5 cm/s
(n = 164)
Average S' ≥ 6.5 cm/s (n = 133)
p-value
Age (y)
81 ± 6
82 ± 5
80 ± 6
0.898
Female Sex (%)
150 (50.5)
84 (51.2)
66 (49.6)
0.816
BMI
27.0 ± 4.8
26.6 ± 4.9
27.6 ± 4.6
0.907
Cardiovascular Risk Factors
Smoker (%)
31 (10.4)
15 (9.1)
16 (12)
0.243
Hypertension (%)
257 (86.5)
144 (87.8)
113 (85)
0.498
Diabetes (%)
81 (27.3)
41 (25)
40 (30.1)
0.360
Dyslipidemia (%)
185 (65.1)
105 (65.2)
80 (65)
1.000
Medical History
Known CAD (%)
143 (51.1)
74 (48.1)
69 (54.8)
0.281
Prior MI (%)
42 (14.1)
32 (19.5)
10 (7.5)
0.004
Prior PCI (%)
75 (25.3)
42 (25.6)
33 (24.8)
0.894
Prior CABG (%)
18 (6.5)
10 (6.5)
8 (6.5)
1.000
Prior stroke (%)
43 (14.5)
25 (15.2)
18 (13.5)
0.742
Previous aortic valve replacement (%)
7 (2.4)
3 (1.8)
4 (3)
0.704
Known PAD (%)
28 (16.3)
20 (21.7)
8 (10)
0.041
Known Atrial Fibrillation (%)
108 (36.4)
74 (45.1)
34 (25.6)
0.001
Clinical Characteristics
Sistolic BP (mmHg)
139 ± 20
134 ± 19
146 ± 19
0.758
Diastolic BP (mmHg)
76 ± 11
75 ± 11
78 ± 10
0.365
Heart Rate (bpm)
70 ± 13
72 ± 13
68 ± 12
0.268
NYHA Class (%)
1
38 (12.8)
17 (10.4)
21 (15.8)
2
98 (33.1)
55 (33.7)
43 (32.3)
3
146 (49.3)
83 (50.9)
63 (47.4)
4
14 (4.7)
8 (4.9)
6 (4.5)
0.284
COPD (%)
33 (11.8)
19 (12.3)
14 (11.1)
0.853
Any conduction disturbance (%)
98 (37.1)
54 (37.8)
44 (36.4)
0.898
PM/ICD at baseline (%)
31 (11)
22 (14.1)
9 (7.1)
0.084
Hb (gr/dL)
12.5 ± 1.8
12.4 ± 1.8
12.5 ± 1.8
0.824
eGFR (Cockroft-Gault)
55.2 ± 16.4
53.1 ± 15.1
57.9 ± 17.6
0.056
Dialysis (%)
5 (1.8)
3 (1.9)
2 (1.6)
1.000
HsTn (URL-fold)
1.35 (0.5—2.5)
1.4 (0.7—2.4)
1.3 (0.3—2.8)
0.335
NT-proBNP (ng/dL)
1820 (615–4418)
2370 (776–5121)
1380 (532–3630)
0.157
Risk Assessment
EuroSCORE II
4.3 (2.6—7.2)
4.9 (2.8—8.3)
3.7 (2.3—5.9)
0.051
STS-PROM
4.4 (2.8—6.7)
4.6 (3.2—7.0)
3.9 (2.2—6.4)
0.365
Implanted prosthesis
Balloon-expandable (%)
144 (48.5)
80 (48.8)
64 (48.1)
Self-expanding (%)
153 (51.5)
84 (51.2)
69 (51.9)
1.000
Values are expressed as n/N of patients (%) or mean ± standard deviation or median and interquartile range
AV aortic valve, BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, ICD implantable cardioverter defibrillator, Hb haemoglobin, HsTn high-sensitivity troponin, STS PROM Society for Thoracic Surgery Predictive Risk of Mortality, MI myocardial infarction; NYHA New York Heart Association, PCI percutaneous coronary intervention, PAD peripheral artery disease, PM pacemaker, TAVI transcatheter aortic valve implantation, URL Upper reference limit
Table 2
Distribution of baseline echocardiographic characteristics in the overall study population and stratified by average S’ status
Overall population (n = 297)
Average S' < 6.5 cm/s
(n = 164)
Average S' ≥ 6.5 cm/s (n = 133)
p-value
Aortic Valve
Max AV gradient (mmHg)
79.1 ± 21.4
70.1 ± 23.9
74.7 ± 17.3
0.003
Mean AV gradient (mmHg)
43.5 ± 13.7
42.1 ± 15.1
45.3 ± 11.6
0.015
AVA (cm2)
0.7 ± 0.2
0.67 ± 0.2
0.75 ± 0.2
0.633
SVi (ml/m2)
39.3 ± 13.2
36.9 ± 12.1
42.2 ± 14.0
0.600
Left Ventricle
LVEF (%)
55.9 ± 13.0
52.5 ± 14.5
60.1 ± 9.4
< 0.001
iLVESV (ml/m2)
28.8 ± 20.9
33.2 ± 23.3
21.6 ± 13.5
< 0.001
iLVEDV (ml/m2)
59.8 ± 24.9
63.4 ± 26.1
53.2 ± 21.2
0.154
iTSD (mm/m2)
19.1 ± 5.6
20.2 ± 5.6
17.5 ± 5.2
0.535
iTDD (mm/m2)
26.1 ± 5.1
27.3 ± 5.5
24.7 ± 4.2
0.016
IVS thickness (mm)
13.6 ± 2.3
13.9 ± 2.6
13.3 ± 2.1
0.134
PW thickness (mm)
12.2 ± 2.0
12.3 ± 2.1
12.0 ± 2.0
0.482
LV mass index (g/m2)
128.4 ± 39.9
138.1 ± 41.3
116.7 ± 34.8
0.214
Valves
AR ≥ moderate (%)
56 (19.2)
33 (20.6)
23 (17.6)
0.552
MR ≥ moderate (%)
73 (24.7)
54 (33.3)
19 (14.3)
< 0.001
TR ≥ moderate (%)
45 (15.4)
35 (21.6)
10 (7.6)
0.001
Diastolic Function
Diastolic dysfunction
289 (97.6)
163 (99.4)
126 (95.5)
0.032
Diastolic dysfunction ≥ 2 grade
167 (57.8)
110 (63.0)
57 (45.3)
< 0.001
E wave (cm/s)
97.1 ± 34.0
101.4 ± 31.6
91.8 ± 36.0
0.565
E Deceleration Time (s)
0.2 ± 0.1
0.2 ± 0.1
0.2 ± 0.1
0.784
A wave (cm/s)
100.4 ± 35.3
92.5 ± 36.1
109.1 ± 32.6
0.293
E/A ratio
1.1 ± 0.9
1.3 ± 1.1
0.9 ± 0.4
< 0.001
Lateral e’ (cm/s)
6.7 ± 2.2
6.6 ± 2.3
6.9 ± 2.2
0.561
Septal e’ (cm/s)
236 (89.1)
136 (91.9)
100 (85.5)
0.114
Average e’ (cm/s)
6.1 ± 1.9
5.8 ± 1.8
6.4 ± 1.9
0.988
E/e’ ratio
17.2 ± 7.6
18.8 ± 7.8
15.1 ± 6.7
0.141
TDI-derived longitudinal systolic function
Septal mitral annular S’ (cm/s)
5.7 ± 1.7
4.7 ± 0.9
7.0 ± 1.5
0.001
Lateral mitral annular S’ (cm/s)
6.9 ± 1.7
5.8 ± 1.2
8.2 ± 1.3
0.080
Average mitral annular S’ (cm/s)
6.2 ± 1.6
5.1 ± 0.9
7.6 ± 1.1
0.259
Others
LAVi (ml/m2)
49.9 ± 20.1
53.5 ± 22.2
45.3 ± 16.2
0.010
sPAP (mmHg)
38.3 ± 14.5
42.0 ± 15.7
33.8 ± 11.3
0.001
TAPSE (mm)
20.5 ± 4.9
19.6 ± 4.4
21.6 ± 5.4
0.239
Pericardial effusion (%)
31 (11)
17 (10.8)
14 (11.3)
1.000
CVP (%)
3
166 (83)
87 (77.7)
79 (89.8)
8
13 (6.5)
10 (8.9)
3 (3.4)
15
21 (10.5)
15 (13.4)
6 (6.8)
0.125
Values are expressed as n/N of patients (%) or mean ± standard deviation
AR aortic regurgitation, AV aortic valve, AVA aortic valve area, CVP central venous pressure, iLEDV indexed left ventricle end-diastolic volume, iLVESV indexed left ventricle end-systolic volume, iTDD indexed tee-diastolic volume, iTSD indexed tele-systolic diameter, IVS interventricular septum, LAVi left atrial volume indexed, LVEF left ventricle ejection fraction, MR mitral regurgitation, sPAP systolic pulmonary artery pressure, PW posterior wall, TAPSE tricuspid annular plane systolic excursion, TDI tissue doppler imaging, TR tricuspid regurgitation, SVi stroke volume index
The mean age was 81 ± 6 years and 150 (50.5%) patients were female. Mean STS PROM was 5.5 ± 4.4% and mean Euroscore II was 6.1 ± 5.8%.
Anzeige
At echocardiographic assessment, 25% of the patients had reduced EF (EF < 50%), 74.3% had LV hypertrophy (LV mass index ≥ 115 gr/m2 for male, ≥ 95 gr/m2 for female), 39.5% had low-flow AS (SVi < 35 ml/mq) and 36.7% had low-gradient AS (mean AS gradient < 40 mmHg).
After a median follow-up of 18 months (IQR 12–18 months), 36 (12.2%) patients died, and 44 (14.8%) died or were hospitalized for HF. Procedural outcomes are reported in Supplementary Table 1 and short-term VARC-2 outcomes are reported in Table 3.
Table 3
Short- and Long-Term Clinical Outcomes according to average S’ status
Average S' < 6.5 cm/s
(n = 164)
Average S' ≥ 6.5 cm/s (n = 133)
P-value
30-day outcomes
All-cause Death (%)
4 (2.5)
1 (0.8)
0.383
Bleeding (%)
Life-threatening
3 (1.9)
8 (6)
0.201
Major
10 (6.2)
7 (5.3)
0.424
AKI stage 2–3 (%)
2 (1.2)
3 (2.3)
0.661
Vascular Complications (%)
Major
15 (9.3)
14 (10.6)
0.910
Minor
19 (11.8)
13 (9.8)
0.736
Myocardial Infarction (%)
0 (0)
1 (0.8)
0.451
Stroke/TIA (%)
3 (1.8)
2 (1.5)
1.000
New Pacemaker (%)
19 (11.8)
20 (15.2)
0.490
Coronary Obstruction (%)
0 (0)
1 (0.8)
0.451
1-year outcomes
All-cause Death (%)
18 (11.5)
6 (4.9)
0.055
HF Hospitalitazion (%)
14 (9.1)
17 (13.8)
0.252
Stroke/TIA (%)
4 (2.5)
2 (2.4)
0.639
Disabling stroke
1 (0.6)
1 (0.8)
0.859
Endocarditis (%)
1 (0.6)
4 (3.3)
0.174
THV Thrombosis (%)
3 (1.9)
4 (3.3)
0.703
NYHA class (%)
1
78 (56.1)
61 (52.6)
2
56 (40.3)
46 (39.7)
3
5 (3.6)
8 (6.9)
0.499
Long-term outcomes
All-cause Death (%)
28 (17.1%)
8 (6.1%)
0.003
A-cause Death/HF hosp. (%)
31 (19.6)
13 (10.2)
0.020
Values are expressed as n/N of patients (%)
AKI acute kidney injury, THV transcatheter heart valve. Other abbreviations as in Table 1
TDI-derived longitudinal left ventricular systolic function
Mean peak systolic average of lateral and septal mitral annular velocities (average S’) was 6.2 ± 1.6 cm/sec. Average S’ was associated with increased all-cause mortality at last follow-up (per 1 cm/sec decrease: HR 1.29, 95% CI 1.03–1.60, p = 0.025). The best average S’ for all-cause mortality was 6.5 cm/sec, obtained from ROC analysis (area under the ROC 0.632, 95%CI 0.538–0.726, p = 0.033).
Patients with reduced average S’ (< 6.5 cm/sec, 55.2% of the study population) had similar clinical characteristics to patients with S’ ≥ 6.5 cm/sec, except for more frequent prior myocardial infarction (19.5% vs 7.5%, p = 0.004) and atrial fibrillation (45.1% vs 25.6%, p = 0.001) (Table 1). At preprocedural echocardiography, patients with reduced average S’ presented with characteristics of more advanced LV remodeling and functional impairment (Table 2). In particular, reduced EF (32.9% vs. 9.2%, p < 0.001), LV hypertrophy (83.5% vs. 60.3%, p < 0.001), low-flow AS (48.0% vs. 31.4%, p = 0.004) and low-gradient AS (42.7% vs. 30.5%, p = 0.021) were more frequent among patients with reduced average S’.
Anzeige
Patients with reduced average S’ had higher Kaplan Meier estimates of all-cause mortality (17.6% vs. 7.5%; HR 2.97, 95%CI 1.36–6.33, p = 0.007) and all-cause mortality or HF hospitalization (20.2% vs. 10.7%; HR 2.02, 95%CI 1.06–3.86, p = 0.027) (Fig. 2). Short-term outcomes were similar regardless of average S’ status (Table 3).
Fig. 2
Kaplan Meier curves for all-cause mortality and all-cause mortality or heart failure hospitalization at 540 days follow-up stratified by average S’. Abbreviations as in Tables 1 and 3. Hazard ratios are derived from Cox proportional hazard models
×
Predictors for adverse clinical outcomes
Multivariable models of predictors for all-cause mortality and of all-cause mortality or HF hospitalization at last follow-up are presented in Table 4. After multivariable adjustment, reduced average S’ (adj-HR: 2.69, 95%CI 1.22–5.93, p = 0.014) and Euroscore II (per 1% increase: 1.05, 95%CI 1.01–1.09, p = 0.009) were independent predictors of all-cause mortality, while reduced average S’ (Adj-HR 2.01, 95%CI 1.05–3.83, p = 0.035) and mean AS gradient (per 1 mmHg decrease: 1.03, 95%CI 1.01–1.06, p = 0.018) were independent predictors of all-cause mortality or HF hospitalization. Results remain consistent also when further adjusting for TAVI Centers (all-cause mortality: Adj-HR 3.09, 95%CI 1.16–8.20, p = 0.024; all-cause mortality or HF hospitalization: Adj-HR 2.96, 95%CI 1.19–7.41, p = 0.038).
Table 4
Predictive factors for long-term all-cause mortality and all-cause mortality or heart failure hospitalization
All-cause mortality*
Univariate
Multivariate
HR (95% CI)
p
HR (95% CI)
p
Age (yrs)
1.07 (1.00 ± 1.15)
0.046
Hb (gr/dL)
0.81 (0.66 ± 0.99)
0.041
Known atrial fibrillation
2.08 (1.08 ± 4.01)
0.028
eGFR (Cockroft-Gault)
0.98 (0.96 ± 1.00)
0.056
Euroscore II (%)
1.06 (1.02 ± 1.10)
0.002
1.05 (1.01–1.09)
0.009
Mean AV gradient (mmHg)
0.98 (0.95 ± 1.00)
0.091
Septal e' (cm/sec)
0.79 (0.62 ± 1.02)
0.066
Average S' < 6.5 cm/s
2.38 (1.08 ± 5.23)
0.030
2.69 (1.22–5.93)
0.014
TR ≥ moderate
1.68 (1.15 ± 2.45)
0.007
ALL-cause mortality/ HF hospitalization*
Univariate
Multivariate
HR (95% CI)
p
HR (95% CI)
p
Age (yrs)
1.07 (1.00 ± 1.15)
0.046
Hb (gr/dL)
0.81 (0.66 ± 0.99)
0.041
Known atrial fibrillation
2.08 (1.08 ± 4.01)
0.028
eGFR (Cockroft-Gault)
0.98 (0.96 ± 1.00)
0.056
Euroscore II
1.06 (1.02 ± 1.10)
0.002
Mean AV gradient (mmHg)
0.98 (0.95 ± 1.00)
0.091
0.97 (0.94–0.99)
0.018
Septal e' (cm/sec)
0.79 (0.62 ± 1.02)
0.066
Average S' < 6.5 cm/s
2.38 (1.08 ± 5.23)
0.030
2.01 (1.05–3.83)
0.035
TR ≥ moderate
1.68 (1.15 ± 2.45)
0.007
*Median follow-up: 540 (363–540) days
CI Confidence Interval, HR Hazard Ratio. Other abbreviations as in Tables 1 and 2
Association of reduced average S’ with all-cause mortality in relevant subgroups
Kaplan Meier estimates for the primary endpoint stratified by average S’ among subgroups of EF, SVi, AS gradient and LV hypertrophy are presented in Fig. 3. A reduced average S’ remained independently associated with all-cause mortality among patients with less severe structural remodeling and functional impairment (preserved EF subgroup: adj-HR 2.98, 95%CI 1.24–7.16, p = 0.014; normal flow subgroup: adj-HR 4.39, 95%CI 1.44–13.40, p = 0.009; high gradient AS subgroup: adj-HR 3.24, 95%CI 1.06–9.96, p = 0.040; no-LV hypertrophy subgroup: adj-HR 2.64, 95%CI 1.03–6.76, p = 0.043).
Fig. 3
Association of average S’ with all-cause mortality across subgroups. Black squares represent hazard ratios (HR); horizontal black lines illustrate CI. Reduced EF: EF < 50%, low flow: stroke volume index < 35 ml/m2, low gradient: mean transvalvular gradient < 40 mmHg, LVH: LV mass index ≥ 115 gr/m2 for male, ≥ 95 gr/m2 for female. *Interaction P testing for an effect modification of the subgroups on the difference in all-cause death between average S’ < 6.5 cm/sec vs. ≥ 6.5 cm/sec. Abbreviations as in Tables 1 and 2
×
Prognostic relevance of average S’ improvement following TAVI
156 (52.5%) patients had available post-TAVI echocardiography with average S’ measurements (median 64 [IQR 42–83] days post-TAVI).
Of 80 patients with reduced average S’ pre-TAVI, 40 (50%) had average S’ “normalization” (≥ 6.5 cm/sec) following TAVI. Patients experiencing average S’ normalization had non significantly different all-cause mortality estimates as compared to patients with normal average S’ pre-TAVI (13.8% vs. 7.4%, log-rank = 0.263), while patients with persistently reduced average S’ had significantly higher all-cause mortality estimates (22.6% vs. 7.4%, p = 0.043).
Discussion
The main finding of our study is that, in patients with severe AS undergoing TAVI, impairment of longitudinal LV systolic function, estimated by average S’ measurements, predicts medium-term all-cause mortality. The association between average S´ and mortality was independent from the patient’s clinical profile and from the echocardiographic parameters of cardiac structure and function, and it was consistently observed among patient subgroups with less severe structural remodeling or functional impairment (including those with preserved EF, normal SVi, high gradient AS or no LV hypertrophy). For clinical purposes, an average S’ below 6.5 cm/sec best defines clinically meaningful reduced longitudinal LV systolic function in symptomatic severe AS.
This is the first study assessing the prognostic value of average S’ among symptomatic patients with severe AS undergoing TAVI. A previous study by Stewart et al. tested the role of average S’ among 183 asymptomatic patients with moderate to severe AS, failing to demonstrate independent predictive value for clinical deterioration after accounting for the severity of AS [4]. In the aforementioned study, average S’ was higher than in our population (median [IQR]: 6.7 [6.0–7.9] cm/sec vs. 6.1 [5.1–7.3] cm/sec) coherently with the different phases of AS natural history. Indeed, the study by Stewart et al. comprised patients in an earlier phase of AS progression, which is likely to have imposed less severe loading conditions and for less time, resulting in a milder morpho-functional LV adverse remodelling. Major differences between both studies may explain the discrepancy in the results. In addition to a much larger study population (n = 297), our study included only symptomatic patients with severe AS eligible for TAVI, while in the study by Stewart only 62% eventually underwent surgical aortic valve replacement. Moreover, mechanisms of reduced longitudinal contractility may vary over the natural history of AS. Indeed, the observation that the association of average S′ with clinical deterioration was fully accounted by AS severity among asymptomatic moderate to severe AS patients suggests that, when afterload-mismatch is the mechanism of decreased longitudinal systolic function, no prognostic implication ensues [4]. Conversely, in more advanced AS disease, maladaptive mechanisms may underlie the longitudinal systolic function impairment entailing worse outcome despite valve replacement [19, 20].
Average S’ was the sole prognostic echocardiographic predictor along with the patient’s clinical risk profile as assessed by the Euroscore II tool. This finding mirrors those of a prior study in which longitudinal systolic function as assessed by global longitudinal strain recapitulated the mortality impact of all other myocardial and valve structural and functional echocardiographic parameters [21]. From a clinical perspective, the implications of our results are two-folded. On one side, average S’ emerges as a powerful indicator that may aid mortality prediction following TAVI, an important goal to improve physician–patient communication and to orientate clinical decision making. On the other side, as average S’ also predicts the composite of mortality or HF hospitalizations, it may be a useful tool to identify those patients more prone to HF progression, that may benefit from closer clinical follow-up to assess fluid status and adequacy of diuretic therapy and, where appropriate, initiation and up-titration of disease-modifying medical treatments.
In our study, reduced average S’ was more frequently observed among patients with previous MI, moderate to severe mitral or tricuspid regurgitation and atrial fibrillation. This highlights how average S’ may reflect the summative effect of different pathophysiological mechanisms related to frequently existing conditions in patients with AS that also affect myocardial function. Of note, the information obtained predicts patient prognosis despite valve replacement. A reduced average S’ (< 6 cm/sec) has been proposed as a highly accurate marker (Sensitivity 100%, Specificity 57%) to screen TAVI candidates for transthyretin cardiac amyloidosis, outperforming speckle-strain imaging parameters [3]. This condition may be prevalent in up to 16% patients with severe AS undergoing TAVI [3] and may be associated with worse outcomes following valve replacement [6], an observation that may be indirectly reflected by the findings of the present study.
Our results were consistent among patients with preserved EF, normal SVi or high gradient AS. These AS subgroups are overall associated with better outcomes following TAVI [5, 22‐24] and show no apparent pump dysfunction in most patients, especially in case of compensatory LV hypertrophy [25]. Our findings reinforce the concept of impaired longitudinal myocardial shortening as an early marker of systolic dysfunction and establish its prognostic value among symptomatic severe AS patients undergoing TAVI also when isolated reduced average S’ is found.
In exploratory analyses, we evaluated the clinical significance of the change in average S’ following TAVI. Among patients with pre-TAVI reduced average S’, longitudinal systolic function recovered in one out of two patients (post-TAVI average S’ ≥ 6.5 cm/sec). Long-term mortality in patients with recovered average S’ was similar to those of patients with pre-TAVI preserved average S’, while prognosis remained poorer for patients with persistently reduced S’. This finding suggests once again that several mechanisms may underlie reduced contractile function in severe AS, entailing differential prognostic implications [1, 19, 20, 26, 27]. More importantly, it adds up to current literature that demonstrated LV reverse remodeling following TAVI to be a positive marker of favorable long-term outcome [27‐29] and it points at post-TAVI average S’ as a reliable echocardiographic feature able to define the patient’s trajectory also within the preserved EF population and at an early assessment, thus providing an advantage over post-TAVI LV mass and EF which recover throughout a longer time course [27]. Since this analysis was carried on a limited proportion of the population with available post-TAVI S’ assessment, it has to be considered hypothesis generating requiring further validation in dedicated studies.
In the present study we assessed longitudinal systolic function by average S’, a TDI-derived parameter of LV long-axis motion measured at the mitral annular level. This approach lacks the ability to reflect segmental functional abnormalities, is affected by signal noise and requires accurate parallel alignment of the Doppler beam with myocardial motion direction. While these drawbacks are at least partly overcome by speckle-tracking echocardiography, whose ability to risk stratify patients in symptomatic severe AS patients has been previously demonstrated [21], the latter is less practical, presents a longer learning curve and requires proprietary software with inter-vendor variability in reference values [13]. To this regard, TDI remains a widely available tool, with great ease of use and high reproducibility which may provide powerful clinical information to orientate risk stratification and patient management across a variety of clinical conditions. Of note, the segmental nature of speckle tracking-derived strain parameters (of clinical relevance across several myocardial diseases) seems to provide limited advantage in severe AS where impaired longitudinal function is primarily reflected at the basal myocardial level. Indeed, basal longitudinal fibers are more exposed to the increased interventricular pressure during isovolumic contraction and are firstly affected by impaired longitudinal shortening as compared to mid-apical segments. This concept is proved on clinical ground, with previous demonstrations of basal longitudinal strain as a more powerful predictor of symptoms and outcomes as compared to global longitudinal strain in AS [30, 31].
Limitations
The findings of this study should be interpreted in the light of several limitations. First, this was a retrospective registry of clinical practice data. Despite the inherent limitations of study design and missing data, our findings have the advantage of generalizability to the real-world clinical setting. Second, only patients with pre-TAVI TDI assessment were included. Although this may in theory represent a source of selection bias, it is unlikely to be clinically significant. Indeed, the availability of TDI measurements seems to depend on the routine operator practice, rather than dictated by clinical reasons. This is also suggested by the clinical and echocardiographic characteristics of the included TAVI population well mirroring current clinical practice. Third, the study sample size was relatively small. However, this represents the largest available study of average S’ in symptomatic severe AS, with consistent results across study subgroups and a grounded physiopathological rationale. Fourth, we did not assess the independent prognostic impact of average S’ against speckle-tracking derived longitudinal strain. As discussed above, this was not the scope of the present analysis and the findings of the study should be interpreted and applied within the boundaries of the study design.
Conclusions
TDI-derived peak systolic average of lateral and septal mitral annular velocities is associated with long-term all-cause mortality among unselected patients with symptomatic severe AS undergoing TAVI. In this population, an average S’ below 6.5 cm/sec best defines clinically meaningful reduced longitudinal LV systolic function and may aid clinical risk stratification.
Declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Ethical approval
The registry was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki.
Consent to participate
All patients provided written informed consent before the procedure.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Prognostic implications of impaired longitudinal left ventricular systolic function assessed by tissue Doppler imaging prior to transcatheter aortic valve implantation for severe aortic stenosis
verfasst von
Guglielmo Gallone Francesco Bruno Teresa Trenkwalder Fabrizio D’Ascenzo Fabian Islas Pier Pasquale Leone Philipp Nicol Costanza Pellegrini Enrico Incaminato Pilar Jimenez-Quevedo Hector Alfonso Alvarez-Covarrubias Renato Bragato Alessandro Andreis Stefano Salizzoni Mauro Rinaldi Adnan Kastrati Federico Conrotto Michael Joner Giulio Stefanini Luis Nombela-Franco Erion Xhepa Javier Escaned Gaetano M. De Ferrari
Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.
Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.
Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.
Auch Personen mit kalt-trockener terminaler Herzinsuffizienz profitieren von einem linksventrikulären Unterstützungssystem (LVAD), wie Daten aus einem US-Register nahelegen. Doch es gibt Besonderheiten.
In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln. Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.
